Patents Assigned to Genentech, Inc.
  • BCMA POLYPEPTIDES AND USES THEREOF
    Publication number: 20090297504
    Abstract: The present invention relates to polypeptides that inhibit APRIL and/or BAFF binding to BCMA, nucleic acid molecules encoding the polypeptides, and compositions comprising the polypeptides. The present invention also relates to methods for treating an immune-related disease or cancer using the polypeptides and compositions of the invention. The present invention also relates to methods for identifying inhibitors of APRIL/BAFF binding to BCMA and APRIL/BAFF signaling.
    Type: Application
    Filed: March 16, 2009
    Publication date: December 3, 2009
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Darshana Ramesh Patel
  • Method for using BOC/CDO to modulate hedgehog signaling
    Patent number: 7625759
    Abstract: The present invention provides for a method of using BOC/CDO hedgehog antagonists to inhibit hedgehog signaling, as well as treating and diagnosing disorders relating to hedgehog signaling or overexpression of hedgehog, including cancer, cell proliferative disorders, and angiogenesis, neurological disorders, as well as other conditions affected by hedgehog signaling such as hair growth, neural stem cell differentiation, chondrogenesis and osteogenesis, lung surfactant production, formation of lamellated bodies in lung cells.
    Type: Grant
    Filed: January 22, 2007
    Date of Patent: December 1, 2009
    Assignee: Genentech, Inc.
    Inventors: Frederic J. de Sauvage, Hua Tian
  • Novel Gene Disruptions, Compositions and Methods Relating Thereto
    Publication number: 20090293137
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO218, PRO228, PRO271, PRO273, PRO295, PRO302, PRO305, PRO326, PRO386, PRO655, PRO162, PRO788, PRO792, PRO940, PRO941, PRO1004, PRO1012, PRO 1016, PRO474, PRO5238, PRO1069, PRO1111, PRO1113, PRO1130, PRO1195, PRO1271, PRO1865, PRO1879, PRO3446, PRO3543, PRO4329, PRO4352, PRO5733, PRO9859, PRO9864, PRO9904, PRO9907, PRO10013, PRO90948, PRO28694, PRO16089, PRO19563, PRO19675, PRO20084, PRO21434, PRO50332, PRO38465 or PRO346 genes.
    Type: Application
    Filed: November 16, 2006
    Publication date: November 26, 2009
    Applicant: Genentech, Inc.
    Inventors: Katherin E. Combs, Frederic J. de Sauvage, Liangfen Fan, Ellen Filvaroff, Allison A. B. Horner, Bryan Irving, Jagath Reddy Juntula, Erin Marie Massey, Dina Rebecca McLain, Laurie Jeanette Minze, Charles Montgomery, Bobby Joe Payne, Heidi Philips, Carolina Rangel, Tracy E. W. Sevaux, Zheng-Zheng Shi, Mary Jean Sparks, Joy Anne Stala, Teresa G. Townsend, Peter Vogel
  • Treatment with anti-VEGF antibodies
    Patent number: 7622115
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: November 24, 2009
    Assignee: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert D. Mass, William Novotny
  • Methods and compositions for modulating prostasin
    Patent number: 7622265
    Abstract: The invention provides methods and compositions related to modulating prostasin.
    Type: Grant
    Filed: February 22, 2006
    Date of Patent: November 24, 2009
    Assignee: Genentech, Inc.
    Inventors: Bin Fan, Daniel K. Kirchhofer
  • Novel Gene Disruptions, Compositions and Methods Relating Thereto
    Publication number: 20090288176
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO286, PRO706, PRO1800, PRO4354, PRO6029, PRO9739, PRO20044, PRO28631 or PRO34128 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
    Type: Application
    Filed: April 18, 2007
    Publication date: November 19, 2009
    Applicant: Genentech, Inc.
    Inventors: Kristi Rae Bollinger, Frederic J. de Sauvage, Joel Edwards, Rosemary Girgis, Leslie Jane Green, Laurie Jeanette Minze, Bobby Joe Payne, Carolina Rangel, Zheng-Zheng Shi, Mary Jean Sparks, Tracy Tzu-Ling Tang, Peter Vogel
  • HER2 ANTIBODY COMPOSITION
    Publication number: 20090285837
    Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
    Type: Application
    Filed: June 8, 2009
    Publication date: November 19, 2009
    Applicant: Genentech, Inc.
    Inventors: YUNG-HSIANG KAO, Martin Vanderlaan
  • HUMANIZED ANTI-TGF-BETA ANTIBODIES
    Publication number: 20090285810
    Abstract: Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.
    Type: Application
    Filed: April 14, 2009
    Publication date: November 19, 2009
    Applicant: GENENTECH, INC.
    Inventors: Camellia W. Adams, Napoleone Ferrara, Ellen H. Filvaroff, Weiguang Mao, Leonard G. Presta, Max L. Tejada
  • ANTIBODIES TO LYMPHOTOXIN-ALPHA
    Publication number: 20090285830
    Abstract: The invention provides various antibodies that bind to lymphotoxin-?, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.
    Type: Application
    Filed: October 11, 2007
    Publication date: November 19, 2009
    Applicant: Genentech, Inc.
    Inventors: Camellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
  • PRO214 polypeptides
    Patent number: 7619062
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those peptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: November 17, 2009
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Napoleone Ferrara, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Kenneth J. Hillan, William I. Wood, Ellen Filvaroff
  • Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs
    Patent number: 7618631
    Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and EGFR-targeted drugs.
    Type: Grant
    Filed: June 16, 2005
    Date of Patent: November 17, 2009
    Assignee: Genentech, Inc.
    Inventor: Mark Sliwkowski
  • HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS
    Publication number: 20090280129
    Abstract: The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein.
    Type: Application
    Filed: August 22, 2008
    Publication date: November 12, 2009
    Applicants: Genentech, Inc., Novartis AG
    Inventors: Jun LIU, Steven J. Shire
  • PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING
    Publication number: 20090281089
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: April 8, 2009
    Publication date: November 12, 2009
    Applicant: Genentech, Inc.
    Inventors: Janet L. Gunzner, Daniel P. Sutherlin, Mark S. Stanley, Liang Bao, Georgette Castanedo, Rebecca L. LaLonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina
  • Methods for treating neuropathy by agonist anti-trk-C monoclonal antibodies
    Patent number: 7615383
    Abstract: The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: November 10, 2009
    Assignee: Genentech, Inc.
    Inventors: Brigitte Devaux, Jo-Anne Hongo, Leonard G. Presta, David L. Shelton
  • Methods and compositions for modulating hyperstabilized c-met
    Patent number: 7615529
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by inhibiting a hyperstabilized c-met protein.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: November 10, 2009
    Assignee: Genentech, Inc.
    Inventors: Monica Kong-Beltran, Dineli M. Wickramasinghe
  • RESPONSES TO IMMUNIZATIONS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH A CD20 ANTIBODY
    Publication number: 20090269339
    Abstract: The present invention provides clinical data evaluating the efficacy of responses to immunizations in rheumatoid arthritis (RA) patients treated with a CD20 antibody.
    Type: Application
    Filed: April 28, 2009
    Publication date: October 29, 2009
    Applicant: Genentech, Inc.
    Inventors: Ariella Kelman, Benjamin L. Trzaskoma
  • HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF
    Publication number: 20090269338
    Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: April 27, 2009
    Publication date: October 29, 2009
    Applicant: Genentech, Inc.
    Inventors: Arthur Huang, Robert Kelley, Henry Lowman, Menno Van Lookeren Campagne, Charles Winter
  • IL-1 RELATED POLYPEPTIDES
    Publication number: 20090269811
    Abstract: The present invention is directed to novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: July 1, 2009
    Publication date: October 29, 2009
    Applicant: Genentech, Inc.
    Inventors: Audrey Goddard, Guohua James Pan
  • METHOD OF DIAGNOSING AND TREATING GLIOMA
    Publication number: 20090269351
    Abstract: The present invention is directed to methods and compositions for the diagnosis, prognosis and treatment of glioma in mammals.
    Type: Application
    Filed: July 6, 2009
    Publication date: October 29, 2009
    Applicant: Genentech, Inc.
    Inventors: Heidi S. Phillips, Liliana Soroceanu
  • NUCLEIC ACIDS ENCODING A RECEPTOR FOR IL-17 HOMOLOGOUS POLYPEPTIDES
    Publication number: 20090269844
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: June 10, 2003
    Publication date: October 29, 2009
    Applicant: Genentech, Inc.
    Inventors: Jian Chen, Ellen Filvaroff, Sherman Fong, Audrey Goddard, Paul Godowski, J. Christopher Grimaldi, Austin Gurney, Hanzhong Li, Kenneth Hillan, Sarah G. Hymowitz, Daniel Tumas, Melissa A. Starovasnik, Menno VanLookeren, Richard Vandlen, Colin Watanabe, P. Mickey Williams, William I. Wood, Daniel Yansura